New book by Larry Connors Click here Improve your trading - See how
Sal. Oppenheim European Healthcare Investors Conference Date: Monday, August 31, 2009 Time: 04:10 pm CET (03:10 pm BST, 10:10 am EDT) Venue: Frankfurt/Main, Germany Presenter: Dr. Simon Moroney, CEO of MorphoSys AG Rodman & Renshaw Annual Global Investment Conference Date: Thursday, September 10, 2009 Time: 10:25 am EDT (04:25 pm CET, 03:25 pm BST) Venue: New York, USA Presenter: Dr. Simon Moroney, CEO of MorphoSys AG German Healthcare Conference Organizer: DZ Bank with Deutsche Borse Group Date: Friday, September 11, 2009 Time: 10:45 am CET (04:45 am EDT, 09:45 am BST) Venue: Zurich, Switzerland Presenter: Mr. Dave Lemus, CFO of MorphoSys AG Bank of America Merrill Lynch Global Healthcare Conference Date: Wednesday, September 16, 2009 Time: 11:20 am BST (12:20 pm CET, 06:20 am EDT) Venue: London, UK Presenter: Dr. Simon Moroney, CEO of MorphoSys AG UBS Global Life Sciences Conference Date: Monday, September 21, 2009 Time: 02:30 pm EDT (08:30 pm CET, 07:30 pm BST) Venue: New York, USA Presenter: Dr. Simon Moroney, CEO of MorphoSys AG Commerzbank Life Sciences Forum Date: Thursday, October 1, 2009 Venue: Frankfurt/Main, Germany Presenter: Dr. Simon Moroney, CEO of MorphoSys AG The PDF versions and, if available, live and archived webcasts of the presentations will be provided at www.morphosys.com. About MorphoSys: MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation, within which it plans to have eight active programs by the end of 2009. Its most advanced program is MOR103, a first-in-class, fully human antibody against GM-CSF. MorphoSys expects to commence a Phase Ib/IIa trial of this antibody in rheumatoid arthritis patients in the second half of 2009. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/ HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R) and RapMAT(R) are registered trademarks of MorphoSys AG This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact MorphoSys: Dr. Claudia Gutjahr-Loser Head of Corporate Communications & IR Tel: +49 (0) 89 / 899 27-122 gutjahr-loeser@morphosys.com Mario Brkulj Senior Manager Corporate Communications & IR Tel: +49 (0) 89 / 899 27-454 brkulj@morphosys.com Jessica Kulpi Specialist Corporate Communications & IR Tel: +49 (0) 89 / 899 27-454 kulpi@morphosys.com This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement. SOURCE: MorphoSys AG For full details for MPHSF click here.
Email Print Archives Feedback Email Article Link
Close X
Related News [MPHSF]
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
Premium Subscription Services
RELATED SITES
Please call 1-213-955-5858 ext. 1
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice. It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN. The Connors Group, Inc. © Copyright 2009 The Connors Group, Inc. All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy. © 2009 The Connors Group, Inc.
|
